CNS Pharmaceuticals Reports Q2 Earnings: Net Loss Narrows to $2.4M

CNS Pharmaceuticals reported a net loss of $2.4 million in Q2 2022, down from $2.5 million in the same period last year. The decrease in net loss is primarily due to a reduction in operating expenses.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has reported its financial results for the second quarter ended June 30, 2025, revealing a net loss of approximately $2.4 million, a decrease from the $2.5 million net loss reported in the same period last year. The reduction in net loss is primarily attributed to a decline in trial costs on the Berubicin trial [1].

The company reported research and development expenses of $1.2 million for the three months ended June 30, 2025, compared to approximately $1.1 million for the same period in 2024. This increase was driven by expenditures related to the preparation of a TPI 287 trial, including drug manufacturing, offsetting the decline in trial costs on the Berubicin trial [1].

General and administrative expenses for the second quarter 2025 amounted to approximately $1.2 million, down from approximately $1.4 million in the same period last year. The decrease was primarily due to reductions in legal and professional expenses, travel expenses, and stock-based compensation, which were partially offset by increases in compensation expense and insurance expense [1].

As of June 30, 2025, CNS Pharmaceuticals had cash on hand of approximately $12.1 million. The company believes that this cash position is sufficient to fund planned operations into the second half of 2026 [1].

CNS Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company's lead program, TPI 287, is an abeotaxane with the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 has shown promising clinical efficacy data, including 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients in a Phase 1 trial treating glioblastoma patients in combination with bevacizumab [1].

References:
[1] https://www.nasdaq.com/press-release/cns-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides